Combo Immuno-Oncology R&D Programs — Recent & Ongoing
By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein
From The September 2015 issue
Read the full magazine article article: Combination Cancer Immunotherapy: A 2015 Update
By careful estimate, companies will have a large number of combination cancer immunotherapy trials in planning or execution as of Jan. 1, 2016.
|
Company |
Trials |
Major Focus |
|
Merck |
62 |
PD-1, CEACAM1 |
|
BMS |
57 |
PD-1, CTLA4, 4-1BB |
|
AZ/MedImmune |
71 |
PD-L1, CTLA4, OX40 |
|
Pfizer [+Merck KgAa] |
32 |
PD-L1, 4-1BB |
|
Roche |
18 |
PD-L1, IDO |
|
Novartis |
16 |
CAR-T |
|
Ono |
5 |
PD-1 |
|
Lilly |
9 |
CXCR4, TGFß |
|
AbbVie |
18 |
BCL-2, SLAM |
|
Sanofi |
3 |
PD-1 |
|
JNJ |
16 |
STING, CD-40 |
|
Celgene |
19 |
PD-L1 (heme), CAR-T |
|
BI |
6 |
mRNA vaccine |
|
Medivation |
6 |
PD-1, Enzalutamide |
|
Heat Biologics |
3 |
ImPACT, ComPACT |
|
Immunovaccine |
3 |
DPX-Survivac |
|
Biotech/Biotech |
137 |
|
|
TOTAL |
478 |
Top Immuno-Oncology Deals Of The Past Year
Although checkpoint inhibitors dominated the R&D news, CAR-T ruled among the richest IO deals in recent months.
|
Companies |
Deal Type |
Value |
Assets |
|
Celgene/Juno |
Co-development Co-promotion Stock Purchase |
About $1B ($150M up front) |
Juno CAR-Ts (chimeric antigen receptor therapies); 10 percent Juno shares; Celgene T cell candidates |
|
Merck/cCAM |
M&A |
Up to $510M ($95M up front) |
cCAM’s checkpoint (CEACAM1) inhibitor. |
|
BMS/Flexus |
M&A |
Up to $1.25B ($850M up front) |
Lead IDO1 inhibitor & IDO discovery platform |
|
Roche/Newlink |
Co-development |
Up to $1B+ ( $150M up front) |
IDO inhibitor, IDO discovery |
|
Pfizer/Cellectis |
R&D “Collaboration” |
Up to $1.6B ($80M up front) |
Cellectis CAR-T platform/candidates |